Interpharma report on Swiss health care costs

19 November 2007

In Switzerland, hospital stays are becoming shorter but more expensive, although the proportion of drug costs in total health care spending has remained constant. The 27th edition of Public Health in Switzerland 2007, published by the Swiss research-based drugmakers' association, the Interpharma, carries the latest statistical evidence on the country's services.

Despite improvements in the length of hospital stays, the Interpharma report notes that, at 11.7 days average duration and a cost of 1,077 Swiss francs ($1,214.10) per patient per day, both figures are high by international standards. Swiss citizens record seven physician visits per year with 78 million diagnoses, with the major areas being cardiovascular and psychiatric conditions.

The Swiss prescription drug bill for 2006 was estimated to be 5.5 billion francs or 10.5% of the total public health care expenditure for the country of 52.7 billion francs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight